Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ç´¢º´¼º ¹ß±âºÎÀüÁõ ȯÀÚ¿¡¼­ À½°æÇظéü³» ¹ß±âÀ¯¹ßÁ¦ Áֻ翡 ÀÇÇÑ ¹ß±â¹ÝÀÀ Erectile Response to Intracavernous Injection of Prostagiandin E1 or Papaverine in Impotence Patient with Diabetes Mellitus

´ëÇѺñ´¢±â°úÇÐȸÁö 1997³â 38±Ç 4È£ p.422 ~ 426
±è¿Ð¹ü, ¼­°æ±Ù, Á¶¿ë°ü,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿Ð¹ü (  ) 
Áß¾Ó´ëÇб³

¼­°æ±Ù (  ) 
Áß¾Ó´ëÇб³
Á¶¿ë°ü (  ) 
Áß¾Ó´ëÇб³

Abstract


Purpose:
@EN To assess the erectile response to intracavernous injection of prostaglandin E1 (PGE 1) or papaverine in the impotence patients with diabetes mellitus(DM), and to determine the factors which would predict good response to either drug.
@ES Materials and Methods:
@EN We injected papaverine (10~60mg) or PGE1 (10~20 mcg) into cavernosal tissues of 305 impotence patients with DM (mean age; 56.1 years). Erectile response was classified into poor, moderate, or good, and was comparatively analyzed according to
kinds
of vasoactive agents, patients' age, duration of DM and impotence, and treatment modality of DM.
@ES Results:
@EN The frequency of good response to PGE1 was significantly higher than to papaverine (61.5% vs. 42.8%; P<0.05). However, no association between erectile response and patients' age, duration of impotence and DM, and treatment modality of DM was
noted.
@ES Conclusions:
@EN Prostaglandin E1 seems to be more effective substance than papaverine for intracavernous injection therapy in impotence patients with DM.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS